Immune Reconstitution Inflammatory Syndrome in People Living with HIV on Antiretroviral Therapy—Insights from a Ten-Year Retrospective Analysis in a Romanian Tertiary Hospital
Diseases · 16.11.2026 · 14 (11) · 423
DOI: 10.3390/diseases14110423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases, online erschienen am 16.11.2026. Verfasst von Alina Orfanu und 13 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Initiation of effective antiretroviral therapy (ART) in people living with HIV (PLWH) may lead to the development of immune reconstitution inflammatory syndrome (IRIS). Characteristics of unmasking versus paradoxical IRIS, and the impact of ART regimens remain incompletely characterized in real-world cohorts.
Methods
We conducted a single-center retrospective analysis of patients diagnosed with IRIS over the period 2015–2025 in a tertiary-care hospital of Infectious Diseases from Bucharest, Romania. Several clinical and biological variables were comparatively analyzed between patients with unmasking versus paradoxical IRIS, and between those receiving integrase strand transfer inhibitors (INSTI)-based versus non-INSTI regimens.
Results
A total of 57 PLWH were included. The median time to IRIS onset was 21 days [IQR = 14]. Unmasking IRIS was diagnosed in 43.9% of cases, while 56.1% of patients developed paradoxical IRIS. Median values of CD4+ and CD8+ T-cell count, CD4/CD8 ratio, HIV RNA, fibrinogen and C-reactive protein prior ART and upon IRIS diagnosis did not significantly vary according to the IRIS subtype and the ART regimen. However, trends in clinical manifestations and paraclinical parameters highlight the heterogeneity of IRIS presentations. Paired analyses showed increases in CD4+ and CD8+ T-cell counts, CD4/CD8 ratio, fibrinogen and CRP, and a decline in HIV RNA (all p < 0.01). Mortality due to IRIS-related complications was 14.0% overall (24.0% in unmasking IRIS versus 6.3% in paradoxical IRIS; two-sided Fisher’s exact p = 0.120). INSTI use was not significantly associated with IRIS subtype after adjustment for baseline CD4+ T-cell count and time since HIV diagnosis (aOR 0.54, 95% CI 0.14–2.09).
Conclusions
This analysis provides insights into the clinical and biological profiles of IRIS and provides valuable descriptive data in clinical practice. Rapid CD4+ T-cell count recovery and HIV RNA decline in presence of elevated inflammatory biomarkers suggest IRIS, but most immunological and virological parameters did not differ significantly by IRIS subtype or ART regimen. Our findings emphasize IRIS variability in clinical cohorts and the importance of further studies to identify more reliable predictive markers for IRIS.
Zitieren
APA
Orfanu, A., Tilişcan, C., Şaran, A., Ganea, O., Mihai, N., Soare, A., Pǎduraru, A., Bǎrbulescu, V., Vasilescu, M., Stratan, L., Molagic, V., Marinescu, A., Aramǎ, Ş. S., & Arama, V. (2026). Immune Reconstitution Inflammatory Syndrome in People Living with HIV on Antiretroviral Therapy—Insights from a Ten-Year Retrospective Analysis in a Romanian Tertiary Hospital. Diseases, 14(11), 423. https://doi.org/10.3390/diseases14110423
Vancouver
Orfanu A, Tilişcan C, Şaran A, Ganea O, Mihai N, Soare A, et al. Immune Reconstitution Inflammatory Syndrome in People Living with HIV on Antiretroviral Therapy—Insights from a Ten-Year Retrospective Analysis in a Romanian Tertiary Hospital. Diseases. 2026;14(11):423. doi:10.3390/diseases14110423
BibTeX
@article{Orfanu2026,
author = {Orfanu, Alina and Tilişcan, Cǎtǎlin and Şaran, Anca and Ganea, Oana and Mihai, Nicoleta and Soare, Adelina and Pǎduraru, Andreea and Bǎrbulescu, Vlad and Vasilescu, Marius and Stratan, Laurențiu and Molagic, Violeta and Marinescu, Adrian-Gabriel and Aramǎ, Ştefan Sorin and Arama, Victoria},
title = {Immune Reconstitution Inflammatory Syndrome in People Living with HIV on Antiretroviral Therapy—Insights from a Ten-Year Retrospective Analysis in a Romanian Tertiary Hospital},
journal = {Diseases},
year = {2026},
volume = {14},
number = {11},
pages = {423},
doi = {10.3390/diseases14110423}
}
EUVIMED